



PALLA PHARMA

## ASX ANNOUNCEMENT

**Monday 4 October 2021**

### **Investor Update Presentation Conference Call Recording**

Palla Pharma Limited (ASX:PAL) advises that a recording of the Investor Update analyst and investor conference call held on Thursday, 30 September 2021 at 4.30pm AEST hosted by Chairman Simon Moore, CEO Giles Moss and CFO Brendan Middleton is now available for viewing.

### **Conference call details**

On-demand viewing is available for 12 months and is set to expire on 30 September 2022:

<https://services.choruscall.com.au/webcast/pallapharma-jfjzpofm.html>

Downloads are available of the presentation (.PDF) of the call from within the webcast frame.

This announcement has been authorised for release by the Chairman.

---

### **For more information please contact:**

#### **Simon Moore**

Chairman  
Palla Pharma Limited  
+61 3 9301 0800

#### **Adrian Mulcahy**

Investor Relations  
Market Eye  
+61 438 630 422 or [ir@pallapharma.com](mailto:ir@pallapharma.com)

#### **Giles Moss**

CEO  
Palla Pharma Limited  
+61 3 9301 0800

#### **Tristan Everett**

Media Enquiries  
Market Eye  
+61 403 789 096 or [media@pallapharma.com](mailto:media@pallapharma.com)

---

### **About Palla Pharma Limited:**

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient, and environmentally sustainable opiate manufacturing process based on a unique water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

#### **Palla Pharma Limited**

PO Box 2139 Melbourne, VIC 3001, Australia

**T** +61 3 9301 0800 / **F** +61 3 9301 0899 / **W** [pallapharma.com](http://pallapharma.com) / **E** [info@pallapharma.com](mailto:info@pallapharma.com)